BERTIS

PANCCHECK®

A blood test solution that enables early diagnosis of pancreatic cancer
with 94% accuracy is under development.

  • About Us
  • Technology​
  • Product
  • Service
  • Career
  • Contact Us
  • Member
  • Mypage
  • Etc
  • Etc
    • Early DetectionMASTOCHECKPANCCHECKOVCHECKOthers
    Early DetectionMASTOCHECKPANCCHECKOVCHECKOthers

    PANCCHECK DEVELOPMENT PROCESS

    While effective early diagnostic methods for pancreatic cancer are currently lacking,
    BERTIS is developing a technology that enables early diagnosis of pancreatic cancer with a small blood sample.

    Through research, we have identified 10 protein biomarkers as a diagnostic marker panel for pancreatic cancer.
    Following algorithm development and validation,
    we have uncovered a combination of markers that demonstrates a high accuracy of 98% and is applicable in clinical settings.

    PANCREATIC CANCER

    Pancreatic cancer is the worst cancer with a 5-year relative survival rate of only 11%
    5-Year relative survival rate of cancers in the U.S. (2011-2017)
    • Prostate

      98%

    • Melanoma
      of the Skin

      93%

    • Breast

      90%

    • Colorectum

      65%

    • Pancreas

      11%

    American Cancer Society, 2022

    The number of deaths and new cases with pancreatic cancer are increasing every year worldwide,
    and it is a fatal cancer in which the number of deaths per new cases in a year is significantly low when compared with other cancers.

    Globocan 2018 & 2020

    PANCREATIC CANCER IS DEADLY.
    IT CAN SPREAD QUICKLY, UNDETECTED, THROUGHOUT THE BODY.

    The pancreas is located deep inside the body; behind the stomach, connected to the duodenum and bile ducts, adjacent to the spleen.
    This location makes pancreatic cancer difficult to detect and hence spreads quickly throughout the body.
    Nearly half of patients (52%) are diagnosed with pancreatic cancer in the distant metastasis stage when cancer cells have already spread to other organs.
    In this condition, the relative survival rate is only 3.1%. Early diagnosis is of the utmost importance with this cancer.

    Additional Information and Data

    go top